According to data published by Cancer Research UK in 2020, ~0.16 million people in the UK die each year due to cancer. Moreover, as per the Globocan report, in 2020, breast cancer in females surpassed the number of lung cancer cases to become the most diagnosed cancer, with an estimated 2.3 million new cases (11.7%). This type was followed by lung cancer, colorectal cancer, prostate cancer, and stomach cancer with the detection rates of 11.4%, 10.0%, 7.3%, and 5.6%, respectively. Overall incidence was 2-fold to 3-fold higher in transitioned than transitioning countries. However, death rates for female breast and cervical cancers were considerably higher in transitioning than transitioned countries. Such a high prevalence of cancer is driving the need for research and study of frozen tissue samples. The studies conducted using frozen tumor tissue samples establish several diagnosis and treatment scopes for this chronic condition.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe frozen tissues samples market at a notable CAGR during the forecast period.
The Europe frozen tissues samples market is segmented on the basis of product type, application, end user, and country. The market, based on product, is segmented into frozen normal tissues samples, frozen tumor tissues samples, and frozen diseased tissue samples. The frozen tissue tumor samples segment held the largest share of the market in 2021. Based on application, the Europe frozen tissues samples market is segmented into disease diagnosis and treatment, cancer and other diseases research, and morphological analysis. In 2021, the cancer and other diseases research segment accounted for the largest share of the market. The Europe frozen tissues samples market, by end user, is segmented into academic and research institutes, hospitals and clinics, diagnostic centers, and others. In 2021, the academic and research institutes segment held the largest market share. Based on country, the Europe frozen tissues samples market is segmented into France, Germany, Italy, UK, Russia, and Rest of Europe.
AMS Biotechnology Ltd.; Audubon Bioscience Co; Bay Biosciences LLC; BioChain Institute Inc.; OriGene Technologies, Inc.; ProteoGenex, Inc.; REPROCELL Inc.; and ZenBio, Inc. are among the leading companies in the Europe frozen tissues samples market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 13.45 Million |
| Market Size by 2028 | US$ 30.32 Million |
| CAGR (2021 - 2028) | 12.3% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Frozen Tissues Samples Market is valued at US$ 13.45 Million in 2021, it is projected to reach US$ 30.32 Million by 2028.
As per our report Europe Frozen Tissues Samples Market, the market size is valued at US$ 13.45 Million in 2021, projecting it to reach US$ 30.32 Million by 2028. This translates to a CAGR of approximately 12.3% during the forecast period.
The Europe Frozen Tissues Samples Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Frozen Tissues Samples Market report:
The Europe Frozen Tissues Samples Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Frozen Tissues Samples Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Frozen Tissues Samples Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)